Significant Progress in MP0712 Clinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Newsfilter
- Clinical Data Support: At the 8th Theranostics World Congress in South Africa, Molecular Partners presented initial imaging and dosimetry data for MP0712, strongly supporting clinical development plans for small cell lung cancer and other DLL3-expressing cancers.
- Tumor Uptake Performance: MP0712 demonstrated significant uptake in tumor lesions with a favorable biodistribution profile, showing low uptake in healthy tissues, indicating its potential therapeutic advantages.
- U.S. Study Launch: The Phase 1/2a study of MP0712 has commenced in the U.S., with initial clinical data expected in 2026, further validating its efficacy in treating small cell lung cancer.
- Strengthened Strategic Collaboration: The partnership between Molecular Partners and Orano Med enhances the development of MP0712, aiming to leverage its unique Radio-DARPin platform to improve the efficacy of targeted radiopharmaceuticals and strengthen its competitive position in tumor-targeted therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.150
Low
8.00
Averages
10.00
High
12.00
Current: 4.150
Low
8.00
Averages
10.00
High
12.00
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Significant Progress in MP0712 Clinical Development
- Clinical Data Support: At the 8th Theranostics World Congress in South Africa, Molecular Partners presented initial imaging and dosimetry data for MP0712, strongly supporting clinical development plans for small cell lung cancer and other DLL3-expressing cancers.
- Tumor Uptake Performance: MP0712 demonstrated significant uptake in tumor lesions with a favorable biodistribution profile, showing low uptake in healthy tissues, indicating its potential therapeutic advantages.
- U.S. Study Launch: The Phase 1/2a study of MP0712 has commenced in the U.S., with initial clinical data expected in 2026, further validating its efficacy in treating small cell lung cancer.
- Strengthened Strategic Collaboration: The partnership between Molecular Partners and Orano Med enhances the development of MP0712, aiming to leverage its unique Radio-DARPin platform to improve the efficacy of targeted radiopharmaceuticals and strengthen its competitive position in tumor-targeted therapies.
Continue Reading
Wall Street Analysts Adjust Ratings on Key Stocks
- Visa Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Visa Inc (NYSE:V) with an Overweight rating and a price target of $400, indicating significant upside from Monday's closing price of $328.49, reflecting confidence in its future growth.
- Intuitive Surgical New Rating: TD Cowen analyst Mathew Blackman initiated coverage on Intuitive Surgical Inc (NASDAQ:ISRG) with a Buy rating and a price target of $660, which, compared to its Monday closing price of $528.81, highlights market recognition of its innovative technologies.
- Molecular Partners Buy Rating: HC Wainwright & Co. analyst Robert Burns initiated coverage on Molecular Partners AG (NASDAQ:MOLN) with a Buy rating and a price target of $13, representing significant upside from its Monday closing price of $4.00, indicating optimistic market expectations regarding its R&D progress.
- Mastercard Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Mastercard Inc (NYSE:MA) with an Overweight rating and a price target of $650, showing a positive outlook based on its Monday closing price of $527.36, reflecting confidence in its market performance.
Continue Reading